AstraZeneca - Research-Based BioPharmaceutical Company

AstraZeneca at the 2018 American Thoracic Society International Congress

Go to page

Science is at the heart of everything we do.

What drives you today?

Ground-breaking science

I have a passion to develop medicines that help patients who don’t otherwise have options. This is very rewarding and motivating for me, and keeps me focused on seeking the evidence, and collaborating with other investigators who share a similar vision to pursue the science that benefits all of mankind.
Roland Kolbeck, PhD, Vice-President R&D Respiratory, Inflammation and Autoimmunity (RIA) at MedImmune

Learn more about MedImmune, our global biologics research and development arm

Publications

Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement.

View our publications

We have

144

projects in our pipeline

View pipeline

CoLAB High Throughput Screening System

Explore our technology

Our new facility in Cambridge will be an open, welcoming and vibrant centre

Explore all our science centres

Corporate Press Release

AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline

24 May 2018

Corporate Press Release

Regulatory submission in Japan for Forxiga in type-1 diabetes

21 May 2018

Our science

At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.

Find out more

Career opportunities

There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it.
Jonathan Dry, Principal Scientist, Bioinformatics, Oncology, Innovative Medicines & Early Development

Meet our people

Acoustic mass spectrometer platform

Explore our technology

Three

strategic science centres

Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries

Find our about our science

Inhibiting stages in the DNA damage response pathway

Our focus areas

Cardiovascular and Metabolic diseases

Oncology

Respiratory

Inflammation and autoimmunity

Neuroscience

Infection and Vaccines

AstraZeneca job search

At AstraZeneca we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.

Search for a job now

Start a career that will help improve life for millions.

Learn more about our School/College Student, Undergraduate, Graduate and Post Doctorate programmes with us in our Early Careers page.

Find your early career now

Working at AstraZeneca

We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. Find out more about our teams and the work they do.

Find out more on the careers section

To partner with AstraZeneca

I often say being in Business Development is having the best job in AstraZeneca in terms of the motivation, interest and challenging work we do with incredibly smart people from science and business on projects that really make a difference for our partners and patients.
Shaun Grady, Vice-President Business Development Operations

See our partnering contacts

Horizon Discovery and AstraZeneca: searching for novel, personalised cancer therapies

See more partnering case studies

Partnering with us

We partner with like-minded organisations and pursue a range of different types of opportunities that are aligned with our portfolio and areas of expertise.

Learn more about our areas of interest

Open Innovation

Our Open Innovation platform is designed to foster open innovation partnerships spanning all stages of drug discovery and development.

Learn more on the Open Innovation site

Corporate Press Release

AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline

24 May 2018

Corporate Press Release

Updated overall survival data for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer presented at AACR

15 April 2018

Collaborate with us

The best science doesn't happen in isolation.

Visit our partnering section

Investor information

“Encouraging launches and strong performances from our newer generation of medicines made a significant contribution to Product Sales in the quarter, paving the way for our anticipated return to growth in 2018. The performance was in line with our expectations and guidance for the year is unchanged."
Pascal Soriot, Executive Director and Chief Executive Officer

Meet our people